Filippo Pietrantonio, MD, Head, Gastrointestinal Oncology Unit, Istituto Nazionale dei Tumori, Milan, Italy
Microsatellite-stable (MSS) colorectal cancer has long resisted immune checkpoint blockade, driven in part by TGF-β-mediated immunosuppression in the tumor microenvironment. At ASCO 2026, Dr. Pietrantonio discusses the daNIS-3 phase II platform study, which evaluates NIS793, a TGF-β pathway inhibitor, combined with anti-PD-1 therapy and standard of care in the second-line setting. He reviews efficacy outcomes including ORR and PFS, examines biomarker signals of microenvironment modulation, and considers what these findings suggest for patient stratification and future combination strategies in this hard-to-treat CRC subgroup.